

### Tata Steel

13 August 2021

#### RESULT UPDATE

**Sector:** Metals **Rating:** BUY  
**CMP:** Rs 1,433 **Target Price:** Rs 1,628

#### Stock Info

Sensex/Nifty	54,843/ 16,364
Bloomberg	TATA IN
Equity shares (mn)	1,130
52-wk High/Low	Rs 1,481/342
Face value	Rs 10
M-Cap	Rs 1,737bn/USD 23bn
3-m Avg volume	USD 284.7mn


#### Financial Snapshot (Rs bn)

Y/E Mar	FY21	FY22E	FY23E
Sales	1,563	2,146	1,982
EBITDA	305	724	520
PAT	92	470	301
EPS (Rs)	77	393	251
PE (x)	14	3	4
EV/EBITDA (x)	7	3	3
RoE (%)	12	42	22
RoCE (%)	13	32	20
Dividend yield (%)	1	2	2

#### Shareholding Pattern (%)

	Jun'21	Mar'21	Dec'20
Promoter	34.5	34.4	34.4
-Pledged	0.5	0.5	1.2
FII	21.9	18.6	16.9
DII	19.3	25.2	25.8
Others	24.3	21.8	23.0

#### Stock Performance (1-year)



#### Rahul Jain

rahuljain@systematixgroup.in  
+91 22 6704 8066

#### Shweta Dikshit

shwetadikshit@systematixgroup.in  
+91 22 6704 8042

#### Results in line with estimates; profit surge to continue in the near-term


Tata Steel (TATA)'s 1QFY22 consolidated EBITDA of Rs 159bn (+1384% YoY and +14% QoQ) was in-line with our estimates. Performance of its three key divisions: 1) Standalone operations EBITDA was Rs 103bn (+696% YoY and +12% QoQ), 2) BSL EBITDA (reported earlier) was Rs 31bn (vs. Rs 2bn YoY and +21% QoQ) and 3) TSE EBITDA was Rs 15bn (+28% QoQ). Earnings were largely driven by a sharp 42% YoY and 8% QoQ surge in realisations. As a result, EBITDA margins surged to USD 523/t (highest since 1QFY12). We expect the strong earnings momentum to flow through in 1HFY22 aided by a return to profitability at the European operations. Debt reduction has accelerated sharply in the wake of the staggered 5mt Kalinganagar, OD expansion project, which has now been restarted. We maintain our FY22E/23E EBITDA as we keep our steel price assumptions unchanged. We continue to value TATA at 5x FY23E and retain our target price of Rs 1,628.

#### Key takeaways from 1QFY22 results

- Tata Steel standalone's realisations at Rs 77k (+66% YoY and 14% QoQ) were the highest-ever. EBITDA/t at USD 523 was the highest since 1HFY09 just before the Global Financial Crisis (GFC). Sales volumes at 2.7mt (+34% YoY and -14% QoQ) were below estimates.
- Tata Steel BSL has reported robust margins at USD 380/t (1,141% YoY and 28% QoQ; highest-ever).
- Tata Steel Europe reported realizations at USD 1,128/t (+46% YoY and +21% QoQ). Pricing buoyancy remains strong in the US and EU, implying more upsides. EBITDA/t at USD 89 has significantly improved vs. EBITDA loss of USD 49/t YoY and +34% QoQ. TSE is all set to report its best operating performance in the coming quarters since 1HFY09. TSE has never fully recovered since the GFC more than a decade ago.
- Tata Steel reduced its net debt by Rs 13bn during the quarter. The debt reduction would have been higher, but for adverse working capital movement of Rs 83bn. Capex during the quarter was Rs 20bn vs. full-year guidance of Rs 100-120bn. The 6mt pellet plant and cold rolling mill (CRM) complex are being accelerated and are set to commission by 1HFY22.


**Maintain BUY:** We maintain our FY22E/23E EBITDA at Rs 724bn/Rs 520bn as we keep our price assumptions unchanged. We retain our target price of Rs 1,628/share. TATA's low-cost raw material advantage is likely to be maintained till 2030 after which its iron ore mines will go for auctions. We assign a multiple of 5x EV/EBITDA and apply a 20% discount to its CWIP. We note that global peer group companies trade at 5-6x EV/EBITDA multiples. The management has guided for annual debt reduction of more than USD 1bn, which is conservative in our view. Given the current steel pricing scenario and benign raw material costs, the debt reduction targets would be easily met, and TATA could become net cash positive by the end of FY24E. **Key risks:** Global macro events such as an unexpected slowdown in China; spillover of the effects of COVID-led slowdown to newer geographies.

Exhibit 1: TATA - quarterly volume growth




Source: Company data, Systematix Research

Exhibit 2: Gradual shift towards high margin India business (mt)




Source: Company data, Systematix Research

Exhibit 3: TATA standalone and cons. quarterly EBIDTA (Rs bn)




Source: Company, Systematix Institutional Research


Exhibit 4: TATA standalone and key sub. quarterly EBIDTA/ton (USD)




Source: Company, Systematix Institutional Research

**Exhibit 5: Strong ASP to drive revenue growth (Rs bn)**


Source: Company, Systematix Institutional Research

**Exhibit 6: Realization boost hinges on cyclical factors (YoY % change)**


Source: Company, Systematix Institutional Research

**Exhibit 7: TSE could achieve EBITDA/t of USD 132 in FY22E...**


Source: Company, Systematix Institutional Research

**Exhibit 8: ...led by benign coal costs**


Source: Company, Systematix Institutional Research

**Exhibit 9: TATA's India margins to remain resilient and gradually improve as domestic volumes pick-up in 2HFY22**


Source: Company, Systematix Institutional Research

**Exhibit 10: Staff costs (USD/ton) to gradually trend lower (still very high compared to JSW Steel)**


Source: Company, Systematix Institutional Research

**Exhibit 11: Cons. PAT to grow led by gradual demand recovery**


Source: Company, Systematix Institutional Research

**Exhibit 12: Consolidated return ratios to improve**


Source: Company, Systematix Institutional Research

**Exhibit 13: Net-working capital (consolidated)**


Source: Company, Systematix Institutional Research

**Exhibit 14: Net debt (consolidated) to equity trend**

Source: Company, Systematix Institutional Research


**Exhibit 15: Net debt (standalone) to equity trend**

Source: Company, Systematix Institutional Research

**Exhibit 16: Net debt (subsidiary) to equity trend**


Source: Company, Systematix Institutional Research

Exhibit 17: EBITDA (consolidated) to OCF conversion




Source: Company, Systematix Institutional Research

Exhibit 18: Consolidated FCF to EV to show steady improvement




Source: Company, Systematix Institutional Research

Exhibit 19: Revenue and PAT growth



Source: Company, Systematix Institutional Research

Exhibit 20: Driven by high volatility in realisations and volumes



Source: Company, Systematix Institutional Research

Exhibit 21: Key assumptions

Key assumptions (Cons)	FY21	FY22E	FY23E
Production (mt)	26.0	27.6	28.2
% change YoY	(9)	6	2
Sales (mt)	26.3	27.6	28.2
% change YoY	1.1	5.1	2.1
Realisations (USD/t)	793	1,022	913
% change YoY	3	29	(11)
EBITDA/ton (USD)	147	345	240
% change YoY	66	135	(31)

Source: Company, Systematix Institutional Research

**Exhibit 22: Quarterly snapshot**

(Rs mn)	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22
<b>Net revenues</b>	<b>242,885</b>	<b>371,540</b>	<b>419,023</b>	<b>499,774</b>	<b>533,718</b>
YoY change (%)					119.7
QoQ change (%)					6.8
<b>EBITDA</b>	<b>5,055</b>	<b>61,108</b>	<b>151,886</b>	<b>141,841</b>	<b>161,106</b>
YoY change (%)					3087.0
QoQ change (%)					13.6
EBITDA Margin (%)	2.1	16.4	36.2	28.4	30.2
<b>Net earnings (adjusted)</b>	<b>-43,736</b>	<b>15,031</b>	<b>94,590</b>	<b>81,530</b>	<b>99,507</b>
YoY change (%)					LP
QoQ change (%)					22.0

Source: Systematix Institutional Research

Target price of Rs 1,628/share based on FY23E EV/EBITDA of 5x (global peer average).

**Exhibit 23: TATA valuation: EV/EBITDA Method, FY23E**

	EBITDA	Multiple	Enterprise Value	Per Share
	(Rs bn)	(x)	(Rs bn)	(Rs)
Consolidated EBITDA	519.9	5.0	2,599	2,144
Less: net debt / (cash)			771	636
Add: CWIP			145	120
Equity value			1,973	1,628
<b>Target price per share</b>			<b>1,628</b>	

Source: Company, Systematix Institutional Research

## FINANCIALS (CONSOLIDATED)

### Profit & Loss Statement

YE: Mar (Rs bn)	FY19	FY20	FY21	FY22E	FY23E
<b>Net revenues</b>	<b>1,591</b>	<b>1,490</b>	<b>1,563</b>	<b>2,146</b>	<b>1,982</b>
Expenditure	1,283	1,311	1,258	1,422	1,462
<b>EBITDA</b>	<b>308</b>	<b>178</b>	<b>305</b>	<b>724</b>	<b>520</b>
Depreciation	73	87	92	95	95
<b>EBIT</b>	<b>235</b>	<b>91</b>	<b>213</b>	<b>629</b>	<b>425</b>
Interest cost	77	76	76	30	20
Exceptionals	-	-	-	-	-
<b>PBT</b>	<b>158</b>	<b>16</b>	<b>137</b>	<b>599</b>	<b>405</b>
Taxes	(67)	26	(57)	(129)	(104)
<b>PAT</b>	<b>91</b>	<b>41</b>	<b>80</b>	<b>470</b>	<b>301</b>
<b>Adjusted PAT</b>	<b>91</b>	<b>41</b>	<b>80</b>	<b>470</b>	<b>301</b>
No of Shares ( mn)	1.2	1.2	1.2	1.2	1.2
<b>Adj. EPS (Rs/share)</b>	<b>76</b>	<b>34</b>	<b>67</b>	<b>393</b>	<b>251</b>

Source: Company, Systematix Institutional Research

### Balance Sheet

YE: Mar (Rs bn)	FY19	FY20	FY21	FY22E	FY23E
Share capital	34	34	20	20	20
Reserves and surplus	655	702	723	1,109	1,328
Minority Interest	24	26	33	33	33
<b>Net worth</b>	<b>713</b>	<b>762</b>	<b>775</b>	<b>1,161</b>	<b>1,381</b>
Total Debt	911	1,133	819	669	569
Non-Current liabilities	209	185	247	247	247
<b>Current liabilities</b>	<b>502</b>	<b>425</b>	<b>614</b>	<b>600</b>	<b>607</b>
<b>Total Sources</b>	<b>2,336</b>	<b>2,504</b>	<b>2,455</b>	<b>2,678</b>	<b>2,804</b>
Net block	1,251	1,352	1,367	1,400	1,483
CWIP	180	189	181	181	181
Non current investments	315	376	305	305	305
<b>Total Non current assets</b>	<b>1,746</b>	<b>1,917</b>	<b>1,853</b>	<b>1,886</b>	<b>1,969</b>
Cash	33	81	58	278	320
Inventories	317	311	333	292	300
Receivables	118	79	95	106	98
Other current assets	122	117	116	116	116
<b>Current Assets</b>	<b>590</b>	<b>587</b>	<b>602</b>	<b>792</b>	<b>834</b>
<b>Total Assets</b>	<b>2,336</b>	<b>2,504</b>	<b>2,455</b>	<b>2,678</b>	<b>2,803</b>

Source: Company, Systematix Institutional Research

### Cash Flow

YE: Mar (Rs bn)	FY19	FY20	FY21	FY22E	FY23E
<b>PBT</b>	<b>158</b>	<b>(14)</b>	<b>138</b>	<b>599</b>	<b>405</b>
Add: Depreciation	76	87	92	95	95
Add: Interest	77	76	76	30	20
Taxes paid	(51)	(21)	(7)	(129)	(104)
Add: other adjustments	(33)	32	(21)	(5)	(5)
WC changes	26	42	165	17	7
<b>Total OCF</b>	<b>253</b>	<b>202</b>	<b>443</b>	<b>607</b>	<b>418</b>
OCF w/o WC changes	227	160	278	590	411
Capital expenditure	(86)	(100)	(65)	(128)	(178)
Change in investments	(209)	(49)	(32)	(35)	(35)
Interest/Dividend Recd.	3	3	4	-	-
<b>Total ICF</b>	<b>(292)</b>	<b>(146)</b>	<b>(93)</b>	<b>(164)</b>	<b>(214)</b>
Free Cash Flows	167	102	378	479	239
Share issuances	(0)	2	32	-	-
Change in borrowings	80	76	(307)	(163)	(113)
Dividends	(14)	(18)	(12)	(30)	(30)
Interest payment	(69)	(74)	(68)	(30)	(20)
Others	(3)	(3)	(2)	1	1
<b>Total Financing CF</b>	<b>(7)</b>	<b>(17)</b>	<b>(356)</b>	<b>(222)</b>	<b>(162)</b>
Net change in cash	(45)	39	(6)	221	42
Opening cash & CE	82	37	75	55	276
Closing cash & CE	36	75	70	276	318

Source: Company, Systematix Institutional Research

### Ratios

YE: Mar	FY19	FY20	FY21	FY22E	FY23E
YoY growth in Revenue	27%	-6%	5%	37%	-8%
YoY growth in EBITDA	38%	-42%	71%	137%	-28%
YoY growth in NI	17%	-33%	51%	409%	-36%
ROCE	13%	6%	13%	32%	20%
ROE	13%	8%	12%	42%	22%
<b>Per Share Numbers (Rs):</b>					
Reported earnings	76	34	67	393	251
Book value	595	636	647	970	1,153
CPS	137	124	154	472	331
<b>Valuations (x)</b>					
P/E	14.1	31.1	16.0	2.7	4.3
EV/EBITDA	7.5	14.2	7.3	2.5	3.3
EV to sales	1.5	1.7	1.4	0.9	0.9
P/BV	1.8	1.7	1.7	1.1	0.9

Source: Company, Systematix Institutional Research



## Institutional Equities Team

<b>Nikhil Khandelwal</b>	<b>Managing Director</b>	<b>+91-22-6704 8001</b>	<b>nikhil@systematixgroup.in</b>
<b>Navin Roy Vallabhaneni</b>	<b>President &amp; Head – IE &amp; ECM</b>	<b>+91-22-6704 8065</b>	<b>navin@systematixgroup.in</b>

### Equity Research

Analysts	Industry Sectors	Desk-Phone	E-mail
Rahul Jain	Metals & Mining	+91-22-6704 8066	rahuljain@systematixgroup.in
Ronak Sarda	Auto, Auto Ancillaries	+91-22-6704 8059	ronaksarda@systematixgroup.in
Rakesh Kumar	Banking, Insurance	+91-22-6704 8041	rakeshkumar@systematixgroup.in
Praful Bohra	Pharmaceuticals and Healthcare	+91-22-6704 8064	prafulbohra@systematixgroup.in
Shubhanshu Mishra	NBFCs & Diversified Financials	+91-22-6704 8024	shubhanshumishra@systematixgroup.in
Sanjeev Kumar Singh	Cement, Building Materials, Paints	+91-22-6704 8017	sanjeevsingh@systematixgroup.in
Premal Kamdar	Consumer Staples	+91-22-6704 8090	premalkamdar@systematixgroup.in
Amar Kedia	Infra, Cap Goods, Logistics, Consumer Durables	+91-22-6704 8084	amarkedia@systematixgroup.in
Ashutosh Joytiraditya	Consumer, Retail	+91-22-6704 8068	ashutoshj@systematixgroup.in
Naushad Chaudhary	Chemicals, Textiles, Building Materials, Midcaps	+91-22-6704 8036	naushadchaudhary@systematixgroup.in
Harsh Mittal	Cement, Building Materials, Paints	+91-22-6704 8098	harshmittal@systematixgroup.in
Poorvi Banka	Auto, Auto Ancillaries	+91-22-6704 8063	poorvibanka@systematixgroup.in
Nikhil Shah	Banking, Insurance	+91-22-6704 8091	nikhilshah@systematixgroup.in
Tausif Shaikh	Pharmaceuticals and Healthcare	+91-22-6704 8046	tausifshaikh@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Shilpashree Venkatesh	Macro-Strategy	+91-22-6704 8078	shilpav@systematixgroup.in

### Equity Sales & Trading

Name		Desk-Phone	E-mail
Vipul Sanghvi	Director and Head - Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Ashok Kumar Agarwal	Sales	+91-22-6704 8058	ashokagarwal@systematixgroup.in
Jigar Kamdar	Sales	+91-22-6704 8060	jigarkamdar@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8033	rahul@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Rahul Thakar	Sales Trading - Derivatives	+91-22-6704 8073	raulthakar@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8050	vipulchheda@systematixgroup.in
Amit Sawant	Dealer	+91-22-6704 8054	amitsawant@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Suketu Vyas	Dealer	+91-22-6704 8050	suketuvyas@systematixgroup.in

### Corporate Access

Audrey Leolyn Mendonca	Assistant Vice President	+91-22-6704 8088	audreymendonca@systematixgroup.in
------------------------	--------------------------	------------------	-----------------------------------

### Production

Yukti Vidyarthi	Editor	+91-22-6704 8071	yukti@systematixgroup.in
Mrunalip Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in

### Operations

Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Sugandha Rane	Assistant Vice President	+91-22-6704 8056	sugandha@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Ravikiran Dasaka	Manager	+91-22-6704 8622	ravikiran@systematixgroup.in
Ravi Agarwal	Assistant Manager	+91-22-6704 8016	raviagarwal@systematixgroup.in



## DISCLOSURES/APPENDIX

## I. ANALYST CERTIFICATION

I, **Rahul Jain, Shweta Dikshit**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

## II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

- There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

## STOCK RATINGS

**BUY (B):** The stock's total return is expected to exceed 15% over the next 12 months.

**HOLD (H):** The stock's total return is expected to be within -15% to +15% over the next 12 months.

**SELL (S):** The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

**NOT RATED (NR):** The analyst has no recommendation on the stock under review.

## INDUSTRY VIEWS

**ATTRACTIVE (AT):** Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

**NEUTRAL (NL):** Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

**CAUTIOUS (CS):** Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

## III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

**SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.**



**Systematix Shares and Stocks (India) Limited:**

**Registered and Corporate address:** The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 34600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | Investment Advisor SEBI Reg. No. INA000010414 | AMFI : ARN - 64917